tiprankstipranks
Advertisement
Advertisement

ATRA Stock Latest News

Atara Biotherapeutics Faces Federal Securities Lawsuit Over Alleged Misstatements About Drug Approval Prospects
Class ActionAtara Biotherapeutics Faces Federal Securities Lawsuit Over Alleged Misstatements About Drug Approval Prospects
1d ago
ATRA
Atara Biotherapeutics files to sell 400K shares of common stock for holders
PremiumThe Fly
Atara Biotherapeutics files to sell 400K shares of common stock for holders
11d ago
ATRA
Atara provides update on tabelecleucel biologics license application
PremiumThe Fly
Atara provides update on tabelecleucel biologics license application
17d ago
ATRA
Atara Plans FDA Type A Meeting on EBVALLO
PremiumCompany Announcements
Atara Plans FDA Type A Meeting on EBVALLO
17d ago
8K
ATRA
Atara, Pierre Fabre seek FDA meeting on EBVALLO
PremiumCompany Announcements
Atara, Pierre Fabre seek FDA meeting on EBVALLO
26d ago
8K
ATRA
Atara Biotherapeutics partner submits Type A meeting request to FDA
PremiumThe FlyAtara Biotherapeutics partner submits Type A meeting request to FDA
26d ago
ATRA
ATRA Earnings this Week: How Will it Perform?
Premium
Pre-Earnings
ATRA Earnings this Week: How Will it Perform?
29d ago
ATRA
Atara Biotherapeutics Extends Royalty Milestone, Issues Warrant
Premium
Company Announcements
Atara Biotherapeutics Extends Royalty Milestone, Issues Warrant
1M ago
8K
ATRA
Atara Biotherapeutics amends HealthCare Royalty purchase, sale agreement
PremiumThe Fly
Atara Biotherapeutics amends HealthCare Royalty purchase, sale agreement
1M ago
ATRA
Tabelecleucel’s Phase 3 EBV+ PTLD Trial Progress Signals Continued Potential for Atara Biotherapeutics
PremiumCompany Announcements
Tabelecleucel’s Phase 3 EBV+ PTLD Trial Progress Signals Continued Potential for Atara Biotherapeutics
2M ago
ATRA
Atara Biotherapeutics downgraded to Hold from Buy at Canaccord (earlier)
PremiumThe Fly
Atara Biotherapeutics downgraded to Hold from Buy at Canaccord (earlier)
2M ago
ATRA
FDA Rejects Atara’s EBVALLO BLA, Commercial Path Uncertain
PremiumCompany Announcements
FDA Rejects Atara’s EBVALLO BLA, Commercial Path Uncertain
3M ago
8K
ATRA
FDA says unable to approve Atara Biotherapeutics Ebvallo BLA in present form
PremiumThe FlyFDA says unable to approve Atara Biotherapeutics Ebvallo BLA in present form
3M ago
ATRA
Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!
Premium
Market News
Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!
3M ago
F
AEP
Atara Biotherapeutics Stock (ATRA) Jumps as FDA Decision on Viral Therapy Nears
Premium
Market News
Atara Biotherapeutics Stock (ATRA) Jumps as FDA Decision on Viral Therapy Nears
3M ago
ATRA
Atara revises tab-cel commercialization milestones with Pierre Fabre
PremiumCompany Announcements
Atara revises tab-cel commercialization milestones with Pierre Fabre
3M ago
8K
ATRA
Atara Biotherapeutics price target raised to $25 from $17 at Canaccord
PremiumThe Fly
Atara Biotherapeutics price target raised to $25 from $17 at Canaccord
3M ago
ATRA
ATRA Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
ATRA Earnings Report this Week: Is It a Buy, Ahead of Earnings?
4M ago
ATRA
Atara Biotherapeutics price target raised to $18 from $16 at Mizuho
PremiumThe Fly
Atara Biotherapeutics price target raised to $18 from $16 at Mizuho
4M ago
ATRA
Atara Biotherapeutics price target raised to $140 from $131 at Mizuho
PremiumThe FlyAtara Biotherapeutics price target raised to $140 from $131 at Mizuho
4M ago
ATRA
Potential FDA Approval of Atara’s Tab-cel Therapy: A Game-Changer for Future Growth and CAR T Program Revitalization
Premium
Ratings
Potential FDA Approval of Atara’s Tab-cel Therapy: A Game-Changer for Future Growth and CAR T Program Revitalization
5M ago
ATRA
Atara Biotherapeutics reports Q3 EPS (32c), consensus (67c)
Premium
The Fly
Atara Biotherapeutics reports Q3 EPS (32c), consensus (67c)
5M ago
ATRA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >